Global Scans · Pharmaceuticals · Weekly Summary

• [New] The US Food and Drug Administration has approved Ozempic tablets, an oral form of semaglutide, with availability expected in the United States in the second quarter of 2026. Rejoy Health
• [New] Biogen is betting that growth from newer drugs - including Alzheimer's treatment Leqembi and rare-disease drugs Skyclarys and Spinraza - will offset its declining multiple sclerosis medicines as competition from generics erode sales. The Edge Malaysia
• [New] By 2026, digital transformation in the pharmaceutical industry will no longer be about isolated technologies, but integration. Voka
• [New] AI-powered pharmacogenomics could reduce adverse drug reactions by up to 30% and improve therapeutic efficacy by 25% across major drug classes. BUSINESS 2.0 NEWS
• [New] With a projected 32.6% CAGR through 2029 and genome sequencing costs plummeting toward $200, AI-powered genomics is reshaping personalized medicine, drug discovery, and clinical diagnostics across the global healthcare ecosystem. BUSINESS 2.0 NEWS
• [New] Pfizer's oncology drug Ibrance will likely see generic competition in 2027, with cardiovascular offerings Eliquis and Vyndaqel next up in 2028. Nasdaq
• [New] Drug-resistant infections could cause 10 million deaths annually by 2050, surpassing deaths from cancer. / USA Market.us Media
• [New] The maker of Wegovy and Ozempic has predicted a sharp drop in revenues in 2026, owing to a push by Donald Trump to lower US weight-loss drug prices, rising competition and the loss of key patent protections. The Business of Fashion
• [New] One of the main questions for drugmakers entering 2026, and one they hope tilts in their favour, is whether the US will successfully pressure Europe to raise its drug prices. MM+M - Medical Marketing and Media
• [New] By 2026, AI will play a more significant role in healthcare, from drug discovery to personalized treatment plans. Data Canvas AI
• [New] Commissioned by the UK government in 2014, if the rate of drug-resistant infections reached 100% by 2050, there would be an estimated 10 million deaths caused by drug-resistant infections. PubMed Central (PMC)
• [New] Roche reported that its experimental obesity drug CT-388 resulted in weight loss in a Phase 2 trial and that it plans to start Phase 3 trials this quarter. MM+M - Medical Marketing and Media
• [New] In 2026, more domestically developed biologics, including CAR-T therapies, antibody-drug conjugates, and novel monoclonal antibodies, are expected to reach late-stage trials or approval. / China China Briefing News
• [New] J&J expects a more pronounced impact from new products in 2026, as it launched some key new products in 2025, like Inlexzoh / TAR-200, a first-of-its-kind drug-releasing system, for treating high-risk non-muscle invasive bladder cancer and Imaavy for treating generalized myasthenia gravis. Yahoo Finance
• [New] In 2026, AI and automation are anticipated to solve talent gaps and economic shifts to drive resilient drug discovery and manufacturing. BioPharm International
• [New] With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the most of its head start with the Wegovy pill. Fierce Pharma
• [New] Structure's oral drug will enter Phase 3 trials in 2026. CNBC
• [New] If 2026 is the year that AI for drug development really takes flight, deal volumes could be much higher than we anticipate. ING Think

Last updated: 10 February 2026